Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how ...
Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...
6d
Fintel on MSNLeerink Partners Downgrades 2seventy bio (TSVT)Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...
23h
Zacks Investment Research on MSN2seventy bio, Inc. (TSVT) Upgraded to Buy: Here's WhyInc. (TSVT) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...
The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible breaches of fiduciary duty and other violations of ...
Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.
Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...
The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.
Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...
GlobalData on MSN6d
BMS to acquire longtime cell therapy partner 2seventy bio for $286mThe deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results